Skip to content

Stereotaxis STXS Free cash flow yield

Free cash flow yield at other companies

Abbott logo
AbbottABT
4.1%+1.2pp
Boston Scientific logo
Boston ScientificBSX
3.7%+1.7pp
Medtronic logo
MedtronicMDT
5.2%+0.4pp
Stryker logo
StrykerSYK
3.6%+1.1pp
ITG
Integer HoldingsITGR
3.3%+0.6pp
Merit Medical Systems logo
Merit Medical SystemsMMSI
5.4%+2.5pp

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-8.0%
Enterprise value$158.77M-12.3%
P/S5.4×-0.4×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Calculated from Stereotaxis’s reported figures.

Based on trailing twelve months.

The official record: Stereotaxis’s 10-K, filed March 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's free cash flow yield?
Stereotaxis (STXS) reported free cash flow yield of -6.7% in Q4 2023.
How has Stereotaxis's free cash flow yield changed year-over-year?
Stereotaxis's free cash flow yield increased by 1.7% year-over-year, from -6.8% to -6.7%.
What is the long-term trend for Stereotaxis's free cash flow yield?
Over 2 years (2021 to 2023), Stereotaxis's free cash flow yield has grown at a 167.4% compound annual growth rate (CAGR), from -0.9% to -6.7%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.